Navigation Links
Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis

OWL Genomics, biotechnological company, has presented at the CIC bioGUNE hold at the Bizkaia Technological Park (Derio), the first DNA chip concerning diagnosis and prognosis of non-alcoholic steatohepatitis (NASH), allowing the discrimination between normal, steatosis and NASH predisposed subjects.

Non alcoholic steatohepatitis is a progressive disease of the liver of unknown etiology, characterized histologically by fatty acid accumulation, hepatocyte damage and inflammation resembling alcoholic hepatitis. NASH is a critical stage in the process that spans from hepatic steatosis to cirrhosis and hepatocarcinoma. NASH is one of the most common causes of elevated aminotransfereases in patients referred for evaluation to hepatologists. Obesity and type-2 diabetes are associated to NASH. Since the prevalence of these diseases is increasing, the prevalence of NASH is also expected to increase and therefore, this disease has become an emerging public issue in United States as well as in other developed countries

The HEPATOCHIP presented at the mentioned forum, has been developed in collaboration with the Hepatology Services of the Clinic Hospital in Barcelona and Príncipe de Asturias Hospital in Alcalá de Henares (Madrid). This chip analyses the co-expression of 85 genes that are related with NASH and is about to be validated in collaboration with the Hepatology Service of Gregorio Marañón Hospital (Madrid).

This HEPATOCHIP method determines the co-expression of genes in the liver tissue sample, providing monitoring treatment regimens to check progression/regression of these liver pathologies.

This HEPATOCHIP can be used as a prognostic tool for NASH-predisposed patients, to make possible more finely tuned diagnosis of this disease and allow healthcare professionals to tailor treatment to individual patients' needs. This chip also assess the efficacy of non-alcoholic steatohepatitis treatment by determining progression or regression of NAS H in patients before, during, and NASH treatment.

###

OWL Genomics, a biotech company focused on providing leading-edge applications in human health with innovative and pioneer technologies within the international scientific community, provides the first product in early diagnosis and therapeutic targets in hepatic diseases.

OWL Genomics is devoted to research into the diagnosis and prevention of liver diseases, through the combination of its state-of-the-art technology and experienced and dedicated personnel.


'"/>

Source:OwlGenomics


Related biology news :

1. New comparative toxicogenomics database
2. Measuring the impact of post-genomics on Mediterranean populations
3. Enlisting genomics to understand flu evolution
4. Drawing with DNA: Bioart illuminates genomics
5. Study reveals genomics of inflammation from severe injury
6. NIH launches comprehensive effort to explore cancer genomics
7. Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy
8. Ticks, flukes, and genomics: Emerging pathogens revealed
9. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
10. Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease
11. Large-scale genomics project will hunt genes behind common childhood diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2018)... ... 21, 2018 , ... VTE can present as deep vein ... significant morbidity and mortality. VTE affects between 300-600,000 Americans annually, with approximately 100,000 ... the leading cause of preventable hospital death and maternal mortality. When used with ...
(Date:9/12/2018)... ... September 10, 2018 , ... IONpathTM, a venture-backed commercial-stage ... Multiplexed Ion Beam Imaging (MIBITM) technology was accepted by the journal Cell and ... shared during a webinar presented by Dr. Mike Angelo on October 2nd, 2018. ...
(Date:9/12/2018)... , ... September 12, 2018 , ... ... spine fusion solutions announced today it has received 510(k) clearance from the U.S. ... complementing its TowerLOX® MIS Pedicle Screw System. , TowerLOX-EXT MIS Extended Tab Pedicle ...
Breaking Biology News(10 mins):
(Date:8/31/2018)... (PRWEB) , ... August 29, 2018 , ... ... Professorships at both the University of Southampton and the Institute of Industrial Science, ... intelligence at sea can dramatically accelerate the exploration and study of hard to ...
(Date:8/29/2018)... ... 28, 2018 , ... CEO and founder of VetStem Biopharma, ... on an allogeneic (donor derived) stem cell product for osteoarthritis in canines at ... September. He is also the organizer of Breakout Session 4: Practitioner Primer on ...
(Date:8/23/2018)... Nev. (PRWEB) , ... August 22, 2018 , ... ... TrialKit ™ for Android on September 1st, making it the first fully-featured app ... iOS and Android devices. Combined, iOS and Android constitute 99 percent of the ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS ... to announce the expansion of their team. Dr. Dawn Dufield, Ph.D., joins KCAS ... innovative large molecule LC-MS/MS group that will specialize in developing quantitative LC-MS/MS assays ...
Breaking Biology Technology: